Identification of HLA-E Binding


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
15 10 2022
Historique:
received: 18 02 2022
accepted: 03 08 2022
pubmed: 13 9 2022
medline: 6 10 2022
entrez: 12 9 2022
Statut: ppublish

Résumé

Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide, posing great social and economic burden to affected countries. Novel vaccine approaches are needed to increase protective immunity against the causative agent

Identifiants

pubmed: 36096642
pii: jimmunol.2200122
doi: 10.4049/jimmunol.2200122
pmc: PMC9536328
mid: NIHMS1828763
doi:

Substances chimiques

Antigens, Bacterial 0
Epitopes, T-Lymphocyte 0
Histocompatibility Antigens Class I 0
Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1555-1565

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI141315
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI127133
Pays : United States

Informations de copyright

Copyright © 2022 by The American Association of Immunologists, Inc.

Références

Int Immunol. 2009 Mar;21(3):257-68
pubmed: 19181932
Nat Immunol. 2003 Sep;4(9):913-9
pubmed: 12897781
J Immunol. 2003 Aug 1;171(3):1369-75
pubmed: 12874227
Antivir Ther. 2005;10(1):95-107
pubmed: 15751767
Immunity. 1999 Nov;11(5):603-13
pubmed: 10591185
PLoS One. 2012;7(9):e46120
pubmed: 23049954
Nat Rev Immunol. 2003 May;3(5):383-91
pubmed: 12766760
Eur J Immunol. 2018 Feb;48(2):293-305
pubmed: 29124751
Nat Immunol. 2012 Apr 22;13(6):579-86
pubmed: 22522492
PLoS Pathog. 2017 May 5;13(5):e1006384
pubmed: 28475642
Tuberculosis (Edinb). 2017 Sep;106:62-72
pubmed: 28802407
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10896-901
pubmed: 12960383
Sci Immunol. 2021 Mar 25;6(57):
pubmed: 33766848
Nat Med. 2018 Feb;24(2):130-143
pubmed: 29334373
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204
pubmed: 9560253
Immunol Lett. 2018 Oct;202:65-72
pubmed: 30172717
J Immunol. 2014 Mar 15;192(6):2885-91
pubmed: 24523505
Mol Immunol. 2013 Jan;53(1-2):126-31
pubmed: 22898188
Front Microbiol. 2014 Oct 08;5:517
pubmed: 25339944
Hum Immunol. 2000 Nov;61(11):1059-65
pubmed: 11137208
Eur J Immunol. 1997 May;27(5):1164-9
pubmed: 9174606
Mol Immunol. 2020 Apr;120:101-112
pubmed: 32113130
Sci Rep. 2016 Nov 28;6:37793
pubmed: 27892960
J Exp Med. 2018 May 7;215(5):1493-1504
pubmed: 29666167
Science. 2016 Feb 12;351(6274):714-20
pubmed: 26797147
PLoS One. 2019 Jan 23;14(1):e0210252
pubmed: 30673723
N Engl J Med. 2019 Dec 19;381(25):2429-2439
pubmed: 31661198
Immunol Rev. 2021 May;301(1):30-47
pubmed: 33529407
PLoS Pathog. 2010 Feb 26;6(2):e1000782
pubmed: 20195504
PLoS Pathog. 2015 Mar 24;11(3):e1004671
pubmed: 25803478
Nucleic Acids Res. 2017 Jul 3;45(W1):W344-W349
pubmed: 28407117
Int J Infect Dis. 2022 Mar 5;:
pubmed: 35257904
J Immunol. 2020 Nov 15;205(10):2861-2872
pubmed: 33020145
Hum Immunol. 2021 Jul;82(7):541-547
pubmed: 33386168
Int J Mol Sci. 2019 Nov 04;20(21):
pubmed: 31690066
Cell. 2018 Jul 26;174(3):672-687.e27
pubmed: 30053426
Front Immunol. 2018 Jul 17;9:1657
pubmed: 30065727
Nat Genet. 2017 Mar;49(3):395-402
pubmed: 28092681
J Immunol. 2004 Nov 1;173(9):5852-62
pubmed: 15494539
Front Immunol. 2018 Jan 25;9:60
pubmed: 29422902
J Biol Chem. 2003 Feb 14;278(7):5082-90
pubmed: 12411439
Vaccine. 2019 May 21;37(23):3022-3030
pubmed: 31040086
Immunogenetics. 2016 Jan;68(1):29-41
pubmed: 26552660
Science. 2019 Oct 18;366(6463):302-303
pubmed: 31624196
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374673
Eur J Immunol. 2020 Dec;50(12):2075-2091
pubmed: 32716529
J Immunol. 2020 Apr 15;204(8):2169-2176
pubmed: 32161099

Auteurs

Paula Ruibal (P)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Kees L M C Franken (KLMC)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Krista E van Meijgaarden (KE)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Marjolein van Wolfswinkel (M)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Ian Derksen (I)

Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands.

Ferenc A Scheeren (FA)

Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.

George M C Janssen (GMC)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.

Peter A van Veelen (PA)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.

Charlotte Sarfas (C)

Research and Development Department, UK Health Security Agency, Salisbury, United Kingdom.

Andrew D White (AD)

Research and Development Department, UK Health Security Agency, Salisbury, United Kingdom.

Sally A Sharpe (SA)

Research and Development Department, UK Health Security Agency, Salisbury, United Kingdom.

Fabrizio Palmieri (F)

National Institute for Infectious Diseases Lazzaro Spallanzani Scientific Institute for Research, Hospitalization and Healthcare, Rome, Italy.

Linda Petrone (L)

National Institute for Infectious Diseases Lazzaro Spallanzani Scientific Institute for Research, Hospitalization and Healthcare, Rome, Italy.

Delia Goletti (D)

National Institute for Infectious Diseases Lazzaro Spallanzani Scientific Institute for Research, Hospitalization and Healthcare, Rome, Italy.

Thomas Abeel (T)

Delft Bioinformatics Lab, Delft University of Technology, Delft, the Netherlands; and.
Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge, MA.

Tom H M Ottenhoff (THM)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.

Simone A Joosten (SA)

Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands; s.a.joosten@lumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH